The Motley Fool Discussion Boards

Previous Page

Industry Discussions / Pharmaceuticals


Subject:  Trius Pharmaceuticals Date:  8/18/2012  10:13 AM
Author:  pedropan1 Number:  889 of 898

Request opinion of other members on Trius.
Main target short term for this company is Staph aureus market, specifically MRSA. Only competing drug is linezolid, a Pfizer product.
Linezolid market roughly 1.5 billion yearly. Trius tint but seems on track.
Interested on hearing from others on possible negatives (or positives)
Copyright 1996-2018 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us